Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
A

Ratings ESG MSCI

Ratings Bristol-Myers Squibb Company: Strengths and Weaknesses

  • The company has a good ESG score relative to its sector, according to MSCI.
Highlights: Bristol-Myers Squibb Company
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • With a P/E ratio at 13.47 for the current year and 12.08 for next year, earnings multiples are highly attractive compared with competitors.
  • The company has a low valuation given the cash flows generated by its activity.
  • This company will be of major interest to investors in search of a high dividend stock.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Analyst opinion has improved significantly over the past four months.
Weaknesses: Bristol-Myers Squibb Company
  • The company's earnings growth outlook lacks momentum and is a weakness.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.

Rating Financials

Bristol-Myers Squibb Company SectorUnited States

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Bristol-Myers Squibb Company SectorUnited States

Global Valuation

Enterprise value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Bristol-Myers Squibb Company SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Bristol-Myers Squibb Company SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Bristol-Myers Squibb Company SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
112B
A
930B
A
527B
BBB
379B
AA
371B
AA
292B
A
270B
A
276B
AAA
268B
A
178B
A
Average 360.34B
AA
Weighted average by Cap.
AA
See all sector ratings
  1. Stock Market
  2. Equities
  3. BMY Stock
  4. Ratings Bristol-Myers Squibb Company